Alex Delaney-Gesing


Bausch + Lomb announces topline results for phase III trial of NOV03 to treat DED associated with MGD

Bausch + Lomb and Novaliq GmbH have announced statistically significant topline data from the first phase 3 trial analyzing the investigational drug NOV03 as a first-in-class eye drop to treat dry eye disease associated with MGD.

Adjusting ophthalmology practice to a pandemic

Find out how one eye care practice has found success in adapting their services to ensure staff/patient safety throughout the pandemic.

Hearing and vision loss may pose high risk for dementia

A diminishment of both hearing and vision is linked to an increased risk for dementia and mental decline, according to a new study.